The choice between Ozempic and Mounjaro comes down to a few concrete facts. Both are once-weekly injections approved for type 2 diabetes, not weight loss. Ozempic is semaglutide; Mounjaro is tirzepatide, which acts on a second receptor as well. In head-to-head diabetes trials tirzepatide tended to lower blood sugar and body weight more, but it also depends on your condition, your coverage, and how you tolerate the medication. There is no universal winner.
What actually separates the two drugs?
Ozempic delivers semaglutide, a GLP-1 receptor agonist. Mounjaro delivers tirzepatide, which stimulates both the GLP-1 and the GIP receptors. That dual action is the main pharmacological difference, and it is the reason tirzepatide has shown larger average effects on weight in obesity studies. Both are given as a once-weekly subcutaneous injection, and both are titrated upward slowly to reduce stomach side effects.
The naming is where people get confused. Semaglutide is sold as Ozempic for diabetes and as Wegovy for weight management. Tirzepatide is sold as Mounjaro for diabetes and as Zepbound for weight management. The molecule is the same across each pair; the brand, the approved use, and the dosing packaging differ. If the underlying question is really semaglutide vs tirzepatide for weight, the weight-management brands are the honest comparison, and the diabetes brands are being used off-label.
What are they approved to treat?
Both Ozempic and Mounjaro are FDA-approved for improving blood sugar in adults with type 2 diabetes, alongside diet and exercise. Ozempic also carries an approval to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established heart disease. Neither is approved for weight loss under these brand names, a point the labeling makes plainly. The prescribing information is worth reading directly for both Ozempic and, for the weight-management form of semaglutide, Wegovy.
See also: strategic momentum for business direction
What does the trial evidence show?
The strongest weight data sit with the weight-management brands, so that is where the useful numbers live. Semaglutide has been studied across the STEP program. STEP 3 paired it with intensive behavioral therapy and showed large average reductions in body weight. STEP 8 compared weekly semaglutide against daily liraglutide and found semaglutide produced more weight loss. STEP 4 tested what happens to people who continue treatment versus switch to placebo, and continuation preserved the loss.
Tirzepatide has its own SURMOUNT program. SURMOUNT-CN studied tirzepatide in Chinese adults with obesity and found meaningful weight reduction versus placebo. These are separate trials with different populations and designs, so treating them as a direct head-to-head would overstate the evidence. The fair summary is that both molecules produce substantial weight loss, and tirzepatide has posted the larger average figures in obesity studies.
How do side effects compare?
The side effect profiles overlap heavily. Nausea, diarrhea, vomiting, and constipation are the common complaints for both, and they cluster around dose increases. Slower titration usually helps. Both carry a boxed warning about thyroid C-cell tumors based on rodent studies, and both list pancreatitis and gallbladder problems among more serious risks. The FDA has also tracked reports and safety questions around these medications, summarized in its consumer safety page on semaglutide products.
Neither drug is clearly kinder to the stomach for everyone. Some people tolerate one and not the other, and that is hard to predict in advance. The realistic expectation is a rough few weeks at each dose step, easing as the body adjusts.
What happens if treatment stops?
This is the part that surprises people, and it matters more than the brand choice. The STEP 1 trial extension followed participants after semaglutide was withdrawn and found that most of the lost weight returned over the following year, with cardiometabolic markers drifting back toward baseline. The tirzepatide side tells the same story: SURMOUNT-4 withdrew the drug from some participants and saw substantial regain, while those who continued kept their results. Both are treatments for a chronic condition. Planning around a short course is planning to regain.
How do cost and access differ?
| Factor | Ozempic (semaglutide) | Mounjaro (tirzepatide) |
|---|---|---|
| Approved use | Type 2 diabetes; cardiovascular risk reduction | Type 2 diabetes |
| Mechanism | GLP-1 receptor agonist | GLP-1 and GIP receptor agonist |
| Coverage for weight | Off-label; often excluded | Off-label; often excluded |
| List price | Above a thousand dollars a month | Above a thousand dollars a month |
What you pay depends far more on coverage than on which brand you pick. Plans that cover these drugs for diabetes often will not cover them for weight, and prior authorization frequently asks for documentation before approving either one. For cash payers, the real comparison is between manufacturer self-pay programs and compounded routes. Both makers now offer direct self-pay pricing well below list, though refill-timing and enrollment conditions apply.
Where do compounded and telehealth options sit?
Compounded semaglutide and tirzepatide are prepared by compounding pharmacies rather than made under an approved application. They are not FDA-approved products, and they have not been through the process that produced the trial evidence discussed above. That is a genuine distinction, not a formality. What they tend to offer is a predictable monthly cash price without insurance involved.
Several named services operate in this space, including Ro, Hims and Hers, Henry Meds, and manufacturer-linked options such as LillyDirect and NovoCare. Supervised telehealth practices such as semaglutide vs tirzepatide publish flat monthly pricing, with prescribing handled by a licensed clinician. The compounded route trades regulatory assurance for cost predictability, and whether that trade makes sense is a conversation for a prescriber who knows the case, not a decision to make from a price page.
Key takeaways
- Ozempic is semaglutide; Mounjaro is tirzepatide, which adds GIP action.
- Both are approved for type 2 diabetes, not weight loss; the weight brands are Wegovy and Zepbound.
- Tirzepatide has posted larger average weight loss, but the trials are not head-to-head.
- Stopping either drug tends to bring the weight back, so plan for the long term.
- Compounded versions are not FDA-approved and belong in a conversation with a prescriber.
Frequently asked questions
Are Ozempic and Mounjaro the same kind of drug?
Not quite. Ozempic is semaglutide, a GLP-1 receptor agonist. Mounjaro is tirzepatide, which acts on both the GLP-1 and GIP receptors. Both are once-weekly injections approved for type 2 diabetes, but the mechanisms differ.
Is either one approved for weight loss?
Ozempic and Mounjaro are both approved for type 2 diabetes, not weight loss. The same molecules are sold under other brand names, Wegovy and Zepbound, for chronic weight management. Prescribing for weight loss under the diabetes brand is off-label.
Which one causes more side effects?
Both commonly cause nausea, diarrhea, constipation, and vomiting, usually worst during dose increases. Neither is clearly gentler for everyone, and individual tolerance varies enough that side effects are hard to predict before starting.
Does the weight come back if I stop?
Trial extensions for both molecules show substantial weight regain after stopping. These are treatments for a chronic condition, not short courses, and the maintenance data reflect that.
Is compounded semaglutide or tirzepatide the same as the brand?
No. Compounded versions are prepared by a compounding pharmacy and are not FDA-approved products. They may contain the same active molecule but have not gone through the approval process behind the brand trial evidence.
